Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial).
- DOI
- 10.3324/haematol.2026.300564
- Published
- 2026 May 7
- Container
- Haematologica
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3324/haematol.2026.300564,
title = {Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial).},
author = {Kikuchi S and Negoro E and Horaguchi R and Fujihira T and Nabe Y and Minemura T and Ono K and Kamihara Y and Wada A and Dang NH and Masaki Y and Miyamoto T and Yamauchi T and Sato T},
year = {2026},
journal = {Haematologica},
doi = {10.3324/haematol.2026.300564},
url = {https://doi.org/10.3324/haematol.2026.300564}
}RIS
TY - JOUR TI - Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial). AU - Kikuchi S AU - Negoro E AU - Horaguchi R AU - Fujihira T AU - Nabe Y AU - Minemura T AU - Ono K AU - Kamihara Y AU - Wada A AU - Dang NH AU - Masaki Y AU - Miyamoto T AU - Yamauchi T AU - Sato T PY - 2026 JO - Haematologica DO - 10.3324/haematol.2026.300564 UR - https://doi.org/10.3324/haematol.2026.300564 ER -
APA
S, K., E, N., R, H., T, F., Y, N., T, M., K, O., Y, K., A, W., NH, D., Y, M., T, M., T, Y., & T, S. (2026). Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial).. Haematologica. https://doi.org/10.3324/haematol.2026.300564